Khoramnia, Ramin http://orcid.org/0000-0002-6237-7773
Figueroa, Marta S.
Hattenbach, Lars-Olof
Pavesio, Carlos E.
Anderesi, Majid
Schmouder, Robert
Chen, Yu
de Smet, Marc D.
Funding for this research was provided by:
Medizinische Fakultät Heidelberg der Universität Heidelberg
Article History
Received: 18 May 2021
Revised: 30 November 2021
Accepted: 6 December 2021
First Online: 21 December 2021
Declarations
:
: Dr. Khoramnia reports grants, personal fees, and non-financial support from Novartis; grants, personal fees, and non-financial support from Bayer; personal fees and non-financial support from Allergan; grants, personal fees, and non-financial support from Roche; grants from Chengdu Kanghong; grants, personal fees, and non-financial support from Alimera; and non-financial support from Heidelberg Engineering outside the submitted work. Dr. Figueroa reports other from Novartis; other from Bayer; other from Allergan; other from Alcon; other from Zeiss; and other from Roche outside the submitted work. Dr. Hattenbach reports grants and personal fees from Novartis Pharma GmbH; grants and personal fees from Bayer AG; personal fees from Pharm Allergan GmbH; grants and personal fees from Roche; grants from Apellis; and grants from Chengdu Kanghong Biotech Co., Ltd. outside the submitted work. Dr. Pavesio reports personal fees from Novartis outside the submitted work. Majid Anderesi, Robert Schmouder, and Yu Chen are employees of Novartis. Dr. de Smet reports personal fees from Tarsius Pharma; personal fees from AbbVie; grants, personal fees, and other from Allergan; personal fees from Biogen; personal fees from MeiraGTx; other from PPD, Inc.; other from Oxular Limited; personal fees and other from Preceyes BV; and other from Novartis outside the submitted work.
: Not applicable.
: Not applicable.